share_log

Brookline Capital Upgrades Oncternal Therapeutics to Buy, Announces $2 Price Target

Benzinga ·  Dec 4, 2023 11:22

Brookline Capital analyst Kemp Dolliver upgrades Oncternal Therapeutics (NASDAQ:ONCT) from Hold to Buy and announces $2 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment